Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 705-714

  Abarientos, Crispin ^a   Sperber, Kirk ^a   Shapiro, Deborah L ^a   Aronow, Wilbert S ^a   Chao, Chun Peng ^a   Ash, Julia Y ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

discoid lupus erythematosus; hydroxychloroquine; pregnancy; rheumatoid arthritis; systemic lupus erythematosus

Indexed keywords

CHLOROQUINE; CYTOCHROME P450; HYDROXYCHLOROQUINE; INTERLEUKIN 6; METHOTREXATE; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; KAPLAN MEIER METHOD; KIDNEY INJURY; LOADING DRUG DOSE; PREGNANCY; PREMATURITY; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052013018     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.566555     Document Type: Review

References (95)

1. Rynes RI. Antimalarial drugs in the treatment of rheumatic diseases. Br J Rheumatol 1997;36:799-805
2. Mellman I, Fuchs R, Helerius A. Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 1986;10:663-700
3. Oda K, Kariyama Y, Yomada E, et al. Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in rat hepatocytes. Biochem J 1986;240:739-45
4. Kyburg D, Bretano F, Gay S. Mode of action of Hydroxychloroquine in RA-evidence of an inhibiting effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006;1:458-9
5. Fessler BJ, Alarcon GS, McGwin G Jr, et al.; and the LUMINA study group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of Hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80
6. Emery P, Suarez-Almazor M. Rheumatoid arthritis. Clin Evid 2003;9:1349-71
7. Tanaka E, Taniguchi A, Urano W, et al. Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 2004;18:233-47
8. Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with 18-week extension. Arthritis Rheum 1999;42:357-65
9. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9
10. Costedoat-Chalumeau N, Amaura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90
11. Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. J Pharm Sci 2007;96:729-46
12. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978;75:3327-31
13. Oda K, Koriyama Y, Yamada E, Ikehara Y. Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes. Biochem J 1986;240:739-45
14. Hurst NP, French JK, Gorjatschko L, et al. Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release. J Rheumatol 1988;15:23-7
15. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-50
16. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982;79:175-8
17. Nowell J, Quaranta V. Chloroquine affects biosynthesis of ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells. J Exp Med 1985;162:1371-6
18. Gammon G, Sercarz EE, Benichou G. The dominant self and the cryptic self: Shaping the autoreactive T-cell repertoire. Immunol Today 1991;12:193-5
19. Fox R. Anti-malarial drugs: Possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996;5(Suppl 1):S4-10
20. Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med 2005;202:817-28
21. Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine. Inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993;20:803-8
22. Wozniacka A, Lesiak A, Narbutt J, et al. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006;15:268
23. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide- induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40
24. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002;168:5303-9
25. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the IL-17 lineage in systemic lupus erythematousus. Curr Opin Rheumatol 2008;20(5):519-25
26. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
27. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med 2005;202:1171-7
28. Brentano F, Schorr O, Gay RE, et al. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheum 2005;52:2656-65
29. Horton CG, Pan ZJ, Farris AD. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm 19 Sep 2010 [Epub ahead of print] PMID: 498980; p11
30. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17
31. Manku MS, Horrobin DF. Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 1976;2:1115-17
32. Loffler BM, Bohn E, Hesse B, et al. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta 1985;835:448-55
33. Gonzalez-Noriega A, Grubb JHVT, Sly WS. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980;85:839-52
34. Kim WU, Yoo SA, Min SY, et al. Hydroxychloroquine potentiates fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 2006;144:503-11
35. Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67-9
36. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987;30:1435-6
37. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and \survival in patients with systemic lupus erythematosus. Lupus 2006;15:577
38. Wallace DJ, Metzger ALVS, Turnbull BA, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease. Reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6
39. Smith GD, Amos TA, Mahler R, et al. Effect of chloroquine on insulin and glucose homoeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987;294:465-7
40. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systemic review. Ann Rheum Dis 2010;69:20-28
41. Alarcon GS, McGwin G, Bertoli AM, et al.; LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from the LUMINA, a multiethnic US cohort. Ann Rheum Dis 2007;66:1168-72
42. Siso A, Ramos-Casals M, Bove A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 2008;17:281-8
43. Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort. Ann Rheum Dis 2007;66:1168-72
44. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is\associated with later onset of systemic lupus erythematosus. Lupus 2007;16:401-9
45. Pons-Estel GJ, Alarcon GS, McGwin G Jr, et al.; Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-9
46. Walker-Bone K, Farrow S. Rheumatoid arthritis. Clin Evid 2006;7:1124
47. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63:2451-65
48. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New Engl J Med 1996;334:1287-91
49. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70
50. Combe B, Didry C, Gutierrez M, et al. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med 1993;23:153-6
51. Kang SM, Choi JH, Moon KC, et al. Methotrexate nodulosis. J Dermatol 1999;26:460-4
52. Mates M, Zeven S, Breuer GS, et al. Desensitization to hydroxychloroquine-experience of 4 patients. J Rheumatol 2006;33:814-16
53. Sontheimer RD. Desensitization to hydroxychloroquine: An alternative explanation. J Rheumatol 2007;34:253-5
54. Donado CD, Diez EM. Successful desensitization for hydroxychloroquine anaphylaxis. J Rheumatol 2010;37(9):1975-6
55. Haehner T, Refaie MO, Muller-Enoch D. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. Arzneimittelforschung 2004;54:78-83
56. Somer M, Kallio J, Pesonen U, et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000;49:549-54
57. Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973-81
58. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology 2003;110:1321-6
59. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: Screening for drug toxicity. Am J Ophthalmol 2002;133:649-56
60. Mackenzie AH. Antimalarial drugs for rheumatoid arthritis. Am J Med 1983;75:48-58
61. Houpt JB. A rheumatologist's verdict on the safety of chloroquine versus hydroxychloroquine liability in off-label prescribing. J Rheumatol 1999;26:1864-6
62. Zuehlke RL, Lilis PJ, Tice A. Antimalarial therapy for lupus erythematosus: An apparent advantage of quinacrine. Int J Dermatol 1981;20:57-61
63. Wolfe F, et al. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:775-84
64. Lai TY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794-807
65. Vroom F, de Walle HE, van de Laar MA, et al. Disease-modifying antirheumatic drugs in pregnancy: Current status and implications for the future. Drug Saf 2006;29:845-63
66. Temprano KK, Bandlamudi R, Moore T. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005;35:112-21
67. Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964;80:407-12
68. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: Recognition and management. Drugs 2007;67:75-93
69. Stafford-Brady FJ, Urowitz MB, Gladman DD, et al. Lupus retinopathy: Patterns, associations, and prognosis. Arthritis Rheum 1988;31:1105-10
70. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002;46:1123-4
71. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006;8:1-19
72. Costedoat-Chalumeau N, Amoura Z, Huong DL, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005;4:111-15
73. Borden MB, Parke AL. Antimalarial drugs in systemic lupus erythematosus: Use in pregnancy. Drug Saf 2001;24:1055-63
74. Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: The British experience. Lupus 1996;5(Suppl 1):S65-6
75. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7
76. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11
77. Buchanan NM, Toubi E, Khamashta MA, et al. Hydroxychloroquine and lupus pregnancy: Review of a series of 36 cases. Ann Rheum Dis 1996;55:486-8
78. Frassi M, Biasini C, Taglieti M, et al. Hydroxychloroquine in pregnant patients with rheumatic disease: A case control observation of 76 treated pregnancies. Lupus 2004;13:755
79. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: Double-blind and placebo-controlled study. Lupus 2001;10:401-4
80. Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009;5:382-90
81. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86-9
82. Motta M, Tincani A, Faden D, et al. Antimalarial agents in pregnancy. Lancet 2002;359:524-5
83. Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure tochloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001;358:813-14
84. Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996;23:1715-18
85. Levy M, Buskila D, Gladman DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-8
86. Suhonen R. Hydroxychloroquine administration in pregnancy. Arch Dermatol 1983;119:185-6
87. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994;13:732-9
88. Chen CY, Chen YH, Lin HC, et al. Increased risk of adverse pregnancy outcomes for hospitalisation of women with lupus during pregnancy: A nationwide population-based study. Clin Exp Rheumatol 2010;28:49-55
89. Sperber K, Hom C, Chao CP, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol 2009;7:9
90. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7;80-5
91. Mintz G, Niz J, Guttierez G, et al. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol 1986;13:732-9
92. Lockshin MD, Reinitz E, Druzin ML, et al. Lupus pregnancy case-control prospective study demonstrate absence of lupus exacerbation during or after pregnancy. Am J Med 1984;77:893-88
93. Petri M, Allbritton J. Fetal outcome of lupus pregnancy: A retrospective case-controlled study of the Hopkins lupus cohort. J Rheumatol 1993;20:650-66
94. Nossent HC, Swaak TJG. Systemic lupus erythematosus. VI: Analysis of the interrelationship with pregnancy. J Rheumatol 1990;17:771-6
95. Garner P, Gulmezoglu AM. Drugs for preventing malaria in pregnant women. Cochrane Database Syst Rev 2006;(4):CD000169